Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Hold" from Brokerages
Precigen, Inc. (NASDAQ:PGEN) has an average "Hold" rating from seven brokerages, with a 12-month average price target of $8.50. This comes despite significant insider selling, including a director selling over 1.9 million shares, and quarterly EPS missing estimates, though revenue exceeded expectations. The company, which focuses on genetic medicines, has institutional ownership of 33.51%.
Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy
Precigen (PGEN) saw its stock drop by 5.7% despite an expert consensus paper recommending its FDA-approved HPV-specific immunotherapy, PAPZIMEOS, as the new first-line treatment for recurrent respiratory papillomatosis (RRP). This endorsement, supported by the RRP Foundation and patient input, strengthens the investment narrative around PAPZIMEOS as a commercially viable lead product. However, the company faces challenges including unprofitability, a high price-to-book multiple, past dilution, insider selling, and share price volatility.
Institutional Investors May Overlook Precigen, Inc.'s (NASDAQ:PGEN) Recent US$110m Market Cap Drop as Long-term Gains Remain Positive
Despite a recent US$110 million market cap drop, institutional investors may not be overly concerned about Precigen, Inc. (NASDAQ:PGEN) due to its impressive 233% one-year return. Institutions hold a significant 31% stake in the company, with the top 5 shareholders controlling 53% of shares, including private equity and hedge funds. Insiders also maintain a substantial holding, indicating alignment with shareholder interests.
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced it will release its second quarter and first half 2022 financial results after the market closes on Monday, August 8, 2022. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and provide a business update. Details for accessing the conference call and event information are available on Precigen's investor relations website.
Bringing a Breakthrough Rare Disease Product to Patients: Q&A with Helen Sabzevari
Helen Sabzevari, president and CEO of Precigen, discusses the recent launch of Papzimeos, the first FDA-approved treatment for recurrent respiratory papillomatosis (RRP). She explains the strategic decision to partner with EVERSANA for commercialization to ensure speed and capital efficiency, highlighting how this approach validated Precigen's operating model and positioned them for future growth in rare disease treatments. Papzimeos offers RRP patients a non-surgical option that reduces surgical burden and addresses the underlying cause of the disease.
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Becomes Preferred First Line RRP Treatment
Precigen's PAPZIMEOS therapy has been recommended as the preferred first-line treatment for adult recurrent respiratory papillomatosis, triggering increased investor interest. The stock, PGEN, has seen significant recent gains but is still considered undervalued by some analysts with a fair value target of $8.50 per share, despite trading at a high P/B ratio compared to peers. Investors are weighing the potential for rapid commercialization against traditional valuation metrics and associated risks.
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
A new expert consensus paper published in The Laryngoscope recommends PAPZIMEOS (zopapogene imadenovec) as the new standard of care first-line treatment for adults with Recurrent Respiratory Papillomatosis (RRP). This marks a significant shift from traditional surgical interventions by addressing the underlying HPV infection, offering the first FDA-approved HPV-specific immunotherapy for RRP. The consensus paper, sponsored by the Recurrent Respiratory Papillomatosis Foundation and authored by 16 leading physicians, emphasizes early therapy, shared decision-making, and a multidisciplinary approach to care.
Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Strong Sell
Zacks Research has downgraded Precigen (NASDAQ:PGEN) from a "hold" to a "strong sell" rating. This downgrade follows significant insider selling, particularly by Director Randal J. Kirk, and the company's miss on quarterly EPS, despite revenue exceeding estimates. Precigen, a biotechnology company, has a negative net margin and a consensus price target of $8.50, though analysts currently rate it as a "Hold" overall.
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next
Precigen's stock (PGEN) rose 5.3% after PAPZIMEOS (zopapogene imadenovec) was recommended as the new first-line standard of care for adult recurrent respiratory papillomatosis (RRP) by an expert consensus paper. This endorsement could reinforce the commercial potential of PAPZIMEOS, but investors should also consider the financial risks, including high current losses, potential dilution, and the need for significant funding to build out the franchise. The article highlights that while this development is a positive for Precigen's commercial narrative, it also underscores the importance of execution for the company given its rich valuation and diverse analyst estimates.
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next
Precigen's stock (PGEN) surged 5.3% following the announcement that its drug, PAPZIMEOS, has been recommended as the new first-line treatment for recurrent respiratory papillomatosis (RRP) by an expert consensus paper. This endorsement is seen as a significant boost to Precigen's commercial narrative for PAPZIMEOS, shifting RRP treatment towards an FDA-approved HPV-specific immunotherapy. However, the article highlights continued risks related to execution on access and reimbursement, cash burn, and potential shareholder dilution, emphasizing that PAPZIMEOS's success is now central to the company's investment outlook.
Patient Capital Management LLC Grows Stake in Precigen, Inc. $PGEN
Patient Capital Management LLC significantly increased its stake in biotechnology company Precigen (NASDAQ:PGEN) by 62.6% in the third quarter, now owning 26.46 million shares worth $87.1 million, making it their 12th largest holding. Despite large insider selling activity, analyst sentiment is mixed but leaning positive, with a "Moderate Buy" consensus and an $8.50 price target against a current trading price of around $4.39. Precigen, with a $1.55 billion market cap and negative EPS, is focusing on genetic medicines and proprietary gene and cell therapy platforms.
New expert consensus shifts RRP treatment from surgery to PAPZIMEOS
A new expert consensus paper published in The Laryngoscope recommends Precigen's PAPZIMEOS (zopapogene imadenovec) as the new standard of care first-line treatment for adults with recurrent respiratory papillomatosis (RRP). This consensus, backed by 16 RRP specialists, advocates for HPV-specific immunotherapy over repeated surgery, emphasizing early therapy, shared decision-making, and the demonstrated safety and long-term durability of PAPZIMEOS. The shift aims to address the underlying HPV infection rather than merely managing symptoms through surgical intervention for this chronic disease.
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
A new expert consensus paper published in The Laryngoscope, sponsored by the Recurrent Respiratory Papillomatosis Foundation (RRPF), recommends PAPZIMEOS (zopapogene imadenovec) as the new standard of care first-line treatment for adults with Recurrent Respiratory Papillomatosis (RRP). This marks a significant shift from traditional surgical interventions, which only address symptoms, towards an HPV-specific immunotherapy. PAPZIMEOS, the first and only FDA-approved HPV-specific immunotherapy, is now positioned as the preferred initial treatment for RRP, aiming for durable disease control.
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
A new expert consensus paper published in The Laryngoscope, sponsored by the Recurrent Respiratory Papillomatosis Foundation, recommends PAPZIMEOS (zopapogene imadenovec) as the new standard of care first-line treatment for adults with recurrent respiratory papillomatosis (RRP). This marks a significant shift from traditional surgical management to an HPV-specific immunotherapy. The recommendation, supported by 16 leading physicians, emphasizes shared decision-making and early therapy to address the underlying HPV infection and potentially provide lasting disease control, moving away from repetitive surgical interventions.
Precigen, Inc. (NASDAQ:PGEN) Sees Large Growth in Short Interest
Precigen, Inc. (NASDAQ:PGEN) experienced a significant 28.2% increase in short interest in December, reaching over 35.5 million shares, representing about 19% of the stock. This surge in short selling occurred alongside a substantial insider sale by Director Randal J. Kirk, who reduced his stake by nearly 85%. Despite these movements, analyst consensus on PGEN remains a "Moderate Buy" with an $8.50 price target, even though the company is currently unprofitable.
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Analysts
Precigen, Inc. (NASDAQ:PGEN) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month target price of $8.50. This comes despite a significant insider stock sale by Director Randal J. Kirk and the company missing Q3 EPS estimates, though revenue beat expectations. Institutional investors have notably adjusted their holdings in the biotechnology company.
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen is highlighting the rapid commercialization and growing market adoption of PAPZIMEOS, its FDA-approved therapy for recurrent respiratory papillomatosis (RRP), at the J.P. Morgan Healthcare Conference. The company reports significant progress with over 200 registered patients, expanding private health plan coverage, and validation of its Marketing Authorization Application by the European Medicines Agency. Precigen expects to reach cash flow break-even with current capital resources as PAPZIMEOS redefines the treatment paradigm for RRP.
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone
Precigen (PGEN) has shown strong commercial momentum for its FDA-approved PAPZIMEOS therapy and received a validated European Medicines Agency filing, leading to significant share price increases over 1 day, 30 days, and 1 year. Despite this, the company's valuation metrics, including a Price to Book ratio of 37.3x and a Discounted Cash Flow model, suggest that the stock is overvalued, trading above its fair value estimate. This indicates that while the market is hopeful about PAPZIMEOS and its pipeline, current profitability and net assets do not justify the high valuation compared to industry peers.
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone
Precigen (PGEN) has seen recent commercial success for PAPZIMEOS, its FDA-approved therapy, along with expanding US payer coverage and a validated EMA filing. Despite strong one-year stock performance, its valuation is considered overvalued with a Price to Book ratio of 37.3x, significantly higher than industry averages, and its fair value estimated at US$0.80 by a discounted cash flow model, compared to its current trading price of US$4.41. Investors are advised to consider the risks and the current market premium on its pipeline over current profitability.
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy?
Precigen, Inc. (PGEN) is seeing rapid commercialization of PAPZIMEOS, its FDA-approved therapy for recurrent respiratory papillomatosis in adults, and is pursuing European marketing authorization. The drug's exclusive status and expanding payer coverage are crucial to the company's investment narrative, especially given prior financial challenges. However, the wide divergence in fair value estimates and valuation multiples underscore the significant execution risk and varying investor expectations for PAPZIMEOS's commercial success.
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy?
Precigen, Inc. (PGEN) is seeing rapid commercialization for PAPZIMEOS, its FDA-approved therapy for recurrent respiratory papillomatosis (RRP) in adults, alongside progress towards European marketing clearance. The drug's exclusive status and expanding payer coverage are key to Precigen's investment narrative, which depends on PAPZIMEOS becoming a significant commercial franchise. However, the company faces deep losses and a rich valuation, making real-world demand and reimbursement critical for its success.
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com
Precigen Inc. announced strong commercial adoption of its FDA-approved RRP treatment, PAPZIMEOS, since its August 2025 approval. Patient enrollment has doubled, and the therapy is now widely prescribed and covered by major insurance plans, Medicare, and Medicaid. The company's stock has seen significant gains, and its Marketing Authorization Application for Europe has been validated.
Iridian Asset Management LLC CT Sells 611,716 Shares of Precigen, Inc. $PGEN
Iridian Asset Management LLC CT reduced its stake in Precigen, Inc. (NASDAQ:PGEN) by 14.3% in the third quarter, selling 611,716 shares and now holding 3,666,946 shares valued at approximately $12.1 million. This sale is part of broader insider selling, including a director selling over 1.9 million shares in December. Despite mixed analyst ratings, the consensus remains a "Moderate Buy" with an average price target of $8.50 for Precigen.
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN) announced that its President and CEO, Helen Sabzevari, PhD, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 7:30 AM PT. Dr. Sabzevari will also participate in a fireside chat with Eversana at the Biotech Showcase on January 12, 2026, at 10:30 AM PT. The company, a biopharmaceutical firm, specializes in developing precision medicines for difficult-to-treat diseases.
Precigen reports strong adoption of RRP treatment PAPZIMEOS
Precigen's PAPZIMEOS, a treatment for recurrent respiratory papillomatosis (RRP), is experiencing rapid commercial adoption after its FDA approval in August 2025. Patient enrollment has doubled, and the treatment is now covered by major health insurance and government programs. The company's stock has seen significant gains, and its Marketing Authorization Application for Europe has been validated.
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com
Precigen announced strong commercial momentum for its recently FDA-approved RRP treatment, PAPZIMEOS, since August 2025. The company has seen patient enrollment double and broad insurance coverage, with the stock reflecting positive sentiment through significant gains. Precigen maintains a strong financial position while continuing to expand access to the treatment.
New RRP treatment spreads nationwide as more insurers agree to cover it
Precigen (PGEN) is rapidly commercializing PAPZIMEOS, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The therapy has seen significant adoption, with patient hub enrollment doubling since November, coverage for approximately 170 million US lives (including Medicare and Medicaid), and EMA validation of its Marketing Authorization Application. This expansion is highlighted ahead of Precigen's presentation at the 44th Annual J.P. Morgan Healthcare Conference, underscoring its impact and value for patients and its potential to reach cash-flow break-even and global expansion.
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen is reporting significant commercialization momentum for PAPZIMEOS, its FDA-approved therapy for RRP, following its approval in August 2025. The company announced over 200 patient hub enrollments, expanding private health plan coverage to 170 million US lives, and the European Medicines Agency's validation of its Marketing Authorization Application. Precigen anticipates reaching cash-flow break-even and global expansion, positioning PAPZIMEOS as a new standard of care for adults with RRP.
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen is reporting significant commercialization momentum and market adoption for PAPZIMEOS, its FDA-approved therapy for recurrent respiratory papillomatosis (RRP). The company announced strong patient hub enrollment, expanding private health plan coverage, and the validation of its Marketing Authorization Application by the European Medicines Agency. Precigen expects this rapid adoption to continue, aiming for PAPZIMEOS to become a standard first-line treatment and to achieve cash-flow break-even while pursuing global expansion.
Precigen, Inc. (PGEN) Stock Analysis: Biotechnology Innovator With Potential 84% Upside
Precigen, Inc. (PGEN) is a clinical-stage biopharmaceutical company focused on gene and cell therapies with a market capitalization of $1.63 billion and impressive revenue growth of 206.60%. Despite current unprofitability due to R&D focus, the company boasts advanced therapeutic platforms, a rich clinical pipeline, and favorable technical stock indicators. Analysts are optimistic, with an average target price suggesting an 84.38% upside for this growth-oriented biotechnology innovator.
Market Sentiment Around Loss-Making Precigen, Inc. (NASDAQ:PGEN)
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company, is anticipated to reach profitability by 2027, according to industry analysts. The company's recent loss expanded to US$426m, but analysts project a profit of US$29m in 2027, driven by an optimistic 66% year-on-year growth forecast. However, the company faces a high debt-to-equity ratio, exceeding 2x, which investors should consider given its current loss-making status.
Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic?
Analysts are optimistic about Precigen, Inc.'s path to profitability, projecting the company to break even just over a year from now in 2027, with anticipated profits of US$29 million. This forecast implies a significant year-on-year growth rate of 66%, signaling high confidence in the biopharmaceutical company's future despite its current loss-making status and high debt-to-equity ratio.
Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic?
Analysts are optimistic about Precigen, Inc.'s path to profitability, projecting it will break even by 2027 with a profit of US$29m, despite a current loss of US$426m and a high debt-to-equity ratio. The company, a biopharmaceutical firm developing gene and cell therapies, is expected to grow 66% year-on-year to hit this target. However, its significant debt level poses an increased risk for investors.
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference – Company Announcement
Precigen, Inc. announced that its CEO, Helen Sabzevari, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. Dr. Sabzevari will also participate in a fireside chat hosted by Eversana at the Biotech Showcase on January 12, 2026. The company, focused on precision medicines for various diseases, provided details for attending these events on its investor relations website.
Will PGEN’s New Drug Make a Splash?
Precigen Inc. (PGEN) shares rose 7.93% following news of FDA designations and positive trial results for its new product, Papzimeos, despite the company's historical financial struggles. The market is weighing the potential of this new drug and strategic realignments against Precigen's track record of declining revenue and negative profitability. Investors are keenly watching whether this optimism will translate into tangible product success and improved financial health.
Kirk sells Precigen shares worth $7.9 million
Director Randal J. Kirk sold 1,900,000 shares of Precigen, Inc. (NASDAQ:PGEN) common stock for approximately $7.9 million on December 22, 2025. This transaction follows a significant 487% surge in Precigen's stock price over the past year. Despite the strong market performance, InvestingPro analysis indicates that Precigen is currently trading above its Fair Value and faces profitability challenges with negative earnings.
Kirk sells Precigen shares worth $7.9 million
Director Randal J. Kirk sold 1,900,000 shares of Precigen, Inc. (NASDAQ:PGEN) common stock for $7,942,150 on December 22, 2025. This transaction comes after a significant 487% surge in Precigen shares over the past year, with the stock trading at $4.38, slightly above Kirk’s sale price of $4.18 per share. Despite the strong price momentum and positive analyst price targets ranging from $8 to $9, the company is still facing profitability challenges, reporting negative earnings of -$1.43 per share in the last twelve months.
Insider Selling: Precigen (NASDAQ:PGEN) Director Sells 1,900,036 Shares of Stock
Precigen (NASDAQ:PGEN) Director Randal Kirk sold 1,900,036 shares of the company's stock on December 22nd for a total of $7,942,150.48. This transaction reduced his ownership by 84.78% to 341,189 shares. The biotechnology company's stock traded up 1.4% to $4.38, with a market capitalization of $1.55 billion, despite recently missing EPS expectations.
Kirk sells Precigen shares worth $7.9 million
Director Randal J. Kirk sold 1,900,000 shares of Precigen, Inc. (NASDAQ:PGEN) for $7.94 million on December 22, 2025, even as the stock has surged 487% over the past year. Despite the sale occurring at $4.18 per share, slightly below the current trading price of $4.38, Kirk maintains indirect ownership of millions of shares through various entities. InvestingPro analysis indicates that Precigen is trading above its Fair Value, faces profitability challenges, and recently reported a significant Q3 2025 revenue beat but an EPS miss.
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock
Jeffrey Kindler, an Independent Director at Precigen, Inc. (NASDAQ:PGEN), recently sold US$856k worth of shares, significantly reducing his holding by 68%. While other insiders bought 60.22k shares, total insider selling over the last year, including a US$6.2m sale by Executive Chairman Randal Kirk, far outstripped buying. The company still maintains a respectable 12% insider ownership, suggesting some alignment with shareholders despite the selling trend.
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock
Precigen Independent Director Jeffrey Kindler recently sold a significant portion of his holdings, netting US$856k and reducing his stake by 68%. This follows a larger sale by Executive Chairman Randal Kirk earlier in the year, indicating a trend of insider selling at prices below the current market value. Despite high insider ownership, the recent selling activity raises questions about future valuation, though insider sales are not always a strong indicator.
PRECIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased
Wolf Haldenstein Adler Freeman & Herz LLP has announced that a securities class action lawsuit has been filed against Precigen, Inc. (formerly Intrexon Corporation) on behalf of investors who purchased securities between May 10, 2017, and September 25, 2020. The lawsuit alleges that the company made materially false and misleading statements regarding its bioconversion platform and financial reporting, and failed to disclose an ongoing SEC investigation. The lead plaintiff deadline for investors to join the case is December 4, 2020.
US High Growth Tech Stocks To Watch December 2025
This article highlights high-growth tech stocks to watch in the US market amid volatility and concerns over an AI bubble. It identifies companies with strong fundamentals and resilience to market pressures, focusing on Precigen (PGEN), Roivant Sciences (ROIV), and Semrush Holdings (SEMR) as key examples. The analysis details their revenue and earnings growth, operational focuses, and recent developments.
Precigen (NASDAQ:PGEN) Trading 5.3% Higher - Here's What Happened
Precigen (NASDAQ:PGEN) saw its stock price rise by 5.3% to $3.6950 on Thursday, although trading volume was significantly lower than its average. Analysts have a "Moderate Buy" consensus with an average price target of $8.50, and insider activity is mixed with the CFO buying shares and a director selling a large number of shares. The company recently missed Q3 EPS estimates but exceeded revenue expectations.
Diametric Capital LP Buys New Holdings in Precigen, Inc. $PGEN
Diametric Capital LP has acquired a new position of 335,057 shares in Precigen, Inc. (NASDAQ:PGEN), valued at approximately $476,000. Institutional investors now own about 33.51% of Precigen, with analysts providing a "Moderate Buy" rating and an average price target of $8.50. The company reported negative EPS and net margin last quarter, while insiders own 47.10% of the stock.
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?
Tang Capital Management recently acquired a new stake in Precigen (NASDAQ:PGEN), investing $40.8 million for 12.4 million shares, representing 1.6% of their reportable assets. This significant investment follows a 282% surge in Precigen's stock over the past year, largely attributed to the FDA approval and successful launch of its gene therapy, PAPZIMEOS. Despite Precigen's financial losses, the commercial execution and regulatory tailwinds suggest a potential turnaround for the company.
Can Precigen's (PGEN) Revenue Surge Offset Concerns About Its Expanding Losses?
Precigen, Inc. (PGEN) reported a significant revenue increase in Q3 2025, reaching US$2.92 million, more than triple the previous year. However, this surge was overshadowed by a substantial rise in net loss to US$146.34 million, raising concerns about the company's liquidity, cash burn, and future funding needs, despite progress in its therapeutic pipeline. The widening losses intensify the financial pressures on Precigen, making financial discipline and access to capital critical near-term risks.
Patient Capital Management LLC Sells 1,103,560 Shares of Precigen, Inc. $PGEN
Patient Capital Management LLC reduced its stake in Precigen, Inc. (NASDAQ:PGEN) by 6.4%, selling over 1.1 million shares, though still holding 16.27 million shares valued at about $23.1 million. This comes as company insiders, including Director Nancy H. Agee and CFO Harry Thomasian, have been buying shares. Precigen currently has a "Moderate Buy" consensus rating from analysts with an average target price of $8.50.
Precigen (PGEN): Valuation in Focus After FDA Approval and Strengthened Cash Position
Precigen (PGEN) recently gained FDA approval for PAPZIMEOS and secured a new credit facility, significantly boosting its stock price by 254.6% year-to-date. Despite a 310.9% 1-year total shareholder return, the company trades at a high price-to-book ratio of 32.4x, suggesting an overvaluation based on future potential rather than current fundamentals. Investors are cautioned to consider this premium valuation against the biotech industry average amidst ongoing losses.
Precigen (PGEN) director Kirk sells shares worth $12.3 million
Randal J. Kirk, a director at Precigen, Inc. (NASDAQ:PGEN), sold 2,966,293 shares of common stock totaling approximately $12.3 million between November 19 and November 21, 2025. These transactions occurred amidst a 20% decline in PGEN's stock over the past week, despite a 330% return over the last year. Analyst targets suggest significant upside potential for PGEN, which currently has a market capitalization of $1.36 billion and strong liquidity.
